Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Says Fiscal Q2 Revenues Rise 53 Percent as Loss Cut by More Than Half

NEW YORK (GenomeWeb News) – Accelr8 today said fiscal second-quarter revenues rose 53 percent as R&D spending decreased 57 percent and losses narrowed 42 percent.
 
Total receipts for the three months ended Jan. 31 increased to $85,000 from 55,000 year over year.
 
More than half the revenues came from license fees, with smaller amounts coming from option fees and from OptiChem sales.
  
R&D spending fell to $250,000 from $570,000 year over year.
 
The company said net losses decreased to $460,000 from $790,000 in the year-ago period, which “reflect[s] the completion of the first BACcelr8r lab prototypes,” Accelr8 President David Howson said in a statement.
 
Accelr8 said it had around $2.1 million in cash and cash equivalents as of Jan. 31.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.